At a time when an average of 248 thousand tests are being conducted daily, the Biojam Holding Group establishes an agreement with its South Korean partner to ensure a rapid response to the growing demand for professional use tests from all Portuguese entities. This is a partnership that allows Biojam, the exclusive representative of PCL COVID19 Ag Gold rapid antigen tests, to place one million tests per week on the national market, which corresponds to 50% of the manufacturer's weekly production capacity. In this way, Portugal positions itself as one of the reference countries for the distribution of PCL tests.
With a clear commitment to expansion and internationalization, the national Biojam also creates a logistical hub in Portugal for the supply of COVID-19 tests destined, in a first phase, for the Iberian market (Portugal and Spain) and PALOP (Portuguese-speaking African countries). As Carlos Monteiro, CEO of Biojam Holding Group, explains, "Portugal is now a strategic distribution point not only for Spain but also for the whole world, without neglecting the domestic market. Biojam has a privileged position that allows its partners to control the flow of incoming and outgoing shipments, as well as ensuring rapid dispatch to various markets. Of course, this aspect ultimately results in cost reduction for partners and end customers."
Another aspect that will contribute to a significant growth in 2022, which is expected to exceed the 30% growth rate seen in the previous year, is the fact that the Biojam Holding Group, as a Portuguese pharmaceutical company, has proven in recent years to be a strategic and solid partner for those looking to enter new markets. "There is no doubt that the security we provide to our partners ultimately is the key to the success of the agreements established in recent times," adds Carlos Monteiro.
Although recognized as one of the first companies to introduce COVID tests to the Portuguese market, especially saliva tests, Biojam also distinguishes itself by other factors: in the last five years alone, it has launched 12 products in the areas of oncology, anesthesiology, women's health, and Nutrigenomics integrated into dietary supplementation, among others. Currently, Biojam's strategy involves not only the launch of new products but also cooperation with Portuguese researchers and universities for the consolidation of new therapies for multi-resistant infections and a focus on integrated artificial intelligence for earlier, easier, and faster diagnosis in various pathologies.
Source: Netfarma
